Circulating Tumor DNA Panel – Colorectal / Lung / Breast

Discover the accelerated NGS with Reliable result for variant with ultra low VAF

Overview

Circulating Tumor DNA Panel for Colorectal / Lung / Breast Cancer

The detection sensitivity for low-frequency variants from sample with limited yield is of great importance to a ctDNA analysis kit.


Celemics has developed NGS ctDNA-based kits for colon, breast, and lung cancer assays through collaborative research with Seoul National University Hospital since 2017. We have integrated our market-leading proprietary technologies including hybridization probe design algorithms, noise removal techniques, and reagent optimization. The panel is thoroughly validated and ready-to-use for clinical diagnostics.

liquid-biopsy
Features & Benefits

Highly Optimized Panel for Clinical Testing with Exceptional Accuracy

This is a complete performance validated panel, conducted with actual clinical patient samples through collaborative research with Seoul National University Hospital. Through the extensive validation studies, Celemics’ ctDNA panel verified assessment of 15 key genes for colorectal cancer, 27 for breast cancer, 28 for lung cancer.

Colorectal Cancer
Sensitivity Freq. 0.5% 100%
Freq. 1.0% 100%
Specificity 97.9%
Breast Cancer
Sensitivity Freq. 0.5% 94.4%
Freq. 1.0% 100%
Specificity 96.3%
Lung Cancer
Sensitivity Freq. 0.5% 100%
Freq. 1.0% 100%
Specificity 100%

Robust BI with Unique Molecular Identifiers(UMI) for ultra-low VAF detection

Receive high-quality data supported by Celemics proprietary
UMI algorithms and Bioinformatics software, enabling effective detection of ultra-low VAF by efficiently removing duplicates and generating consensus read, which will result in increased sequencing efficiency


Along with exclusive barcodes, Celemics also provides
our own-designed modular software allows seamless integration of Bioinformatics solution, from FASTQ to clinical report.

Proven variant detection performance even with low-yield challenging clinical sample

Detection sensitivity and specificity of ctDNA panels have been tested and verified with various actual clinical specimen.


Even with the template DNA amount as low as 10 ng, the panel demonstrated market-leading performance with superior sensitivity and specificity and these panels been supported by numerous peer review publications.

Exclusive Bioinformatics algorithms for accurate analysis

Celemics applies algorithms for eliminating the sequencing error and reducing noise to increase the detection sensitivity and specificity. By applying these exclusive pipeline features, we can provide accurate and reliable sequencing results to our customers.


We continuously monitor and improve of the noise removal technology by data accumulation

Workflow

Simple workflow of circulating tumor DNA panel

  • Able to assess ctDNA with ultra-low variant allele frequency (VAF)
  • Simple workflow and easy-to-follow protocol
  • Modular algorithm to be applied in the existing pipeline.
  • Retrieves more unique reads than that from conventional duplication removal algorithms, reducing sequencing costs
  • Noise removal and accurate calls due to proprietary consensus sequence generation algorithm

Bioinformatics SW for Noise Reduction and Duplicate Read Recovery

  • Minimizes the noise for accurate analysis of variants with ultra-low VAF from ctDNA
  • Generates consensus read to support noise suppression
  • Continuous improvement of the noise removal technology by data accumulation

Specification

*Gene Add-On Service: Genes can be added by customer’s request.
Colorectal Cancer Breast Cancer Lung Cancer
Gene count* 15 genes 27 genes 28 genes
Covered region Whole CDS Whole CDS (8 genes)
Hotspot exonic region (20 genes)
Target size 49 kb 99 kb 47 kb
Mutation type SNV, Indel
Sample type (amount) Plasma (>20 ng of cfDNA)
Platform  All sequencers from illumina
Bioinformatics pipeline 1. Primary and Secondary analysis result (FASTQ to VCF)
2. Secondary Analysis: CNV, Large InDel
3. Tertiary Analysis: Clinical interpretation
* Linux-based consensus read generation software

Specification - Gene List

  • 15 genes | Gene count
  • 49 kb | Target Size
  • Whole CDS | Target Region 
ctDNA Colorectal Cancer Panel APC ATM BRAF EGFR ERBB2 FBXW7 KRAS MET
NRAS PDGFRA PIK3CA PTEN SMAD4 TCF7L2 TP53
  • 27 genes | Gene count
  • 99 kb | Target Size
  • Whole CDS | Target Region
ctDNA Breast
Cancer Panel
AKT1 APC AR BRCA1 BRCA2 CCND1 CDH1 EGFR
ERBB2 ESR1 FGFR1 FGFR2 GATA3 IGF1R KIT KRAS
MAP2K4 MAP3K1 MDM2 MYC NF1 PIK3CA PIK3R1 PTEN
RB1 TOP2A TP53          
  • 28 genes | Gene count
  • 47 kb | Target Size
  • Whole CDS for 8 genes and Hotspot exonic region for 20 genes, 3 Intronic regions | Target Region
ctDNA Lung
Cancer Panel
AKT1 ALK ARAF ARID1A BRAF CBL CDKN2A EGFR
ERBB2 HRAS KEAP1 KRAS MAP2K1 MET MTOR NF1
NRAS NTRK1 NTRK2 PIK3CA PTEN RB1 RIT1 ROS1
SETD2 STK11 TP53 U2AF1        

Related Products

related-product

Highly optimized, user- convenient NGS library preparation kit for all Celemics panels

Celemics Analysis Service

End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis

Streptavidin Bead

Incomparable quality magnetic bead for simple, flexible, and reproducible purification

related-product

Market-leading yield and accuracy with minimized PCR bias. Includes all reaction components for PCR

Resources

Technical Resources

[Product Sheet] Celemics Liquid Biopsy Panel

[Product Overview] Circulating Tumor DNA Panel (Colorectal, Breast, Lung)

Celemics Target Enrichment Panel Overview

Celemics Products & Services

Safety Data Sheets

MSDS_Liquid Biopsy Panel_Illumina_Enzymeplus

MSDS_Liquid Biopsy Panel_Illumina

MSDS_Liquid Biopsy Panel_Thermo Fisher

MSDS_Liquid Biopsy Panel_MGI_EnzymePlus

MSDS_Liquid Biopsy Panel_MGI

References

Epigenomics

Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel

Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.

 

10.2217/epi-2021-0477


View Detail >

Investig Clin Urol

Germline pathogenic variants in unselected Korean men with prostate cancer

So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.

 

DOI 10.4111/icu.20220044


View Detail >

Scientific Reports

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers

Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.

 

DOI 10.1038/s41598-022-05931-3


View Detail >

BMC Medical Genomics

A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report

Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.

 

DOI 10.1186/s12920-022-01191-2


View Detail >